Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease

被引：21

作者：

Carella, Angelo Michele ^{[1
]}

Biasco, Samantha ^{[1
]}

Nati, Sandro ^{[1
]}

Congiu, Angela ^{[1
]}

Lerma, Enrica ^{[1
]}

机构：

[1] Azienda Osped Univ San Martino, Dept Oncohematol, Div Hematol 1, I-16132 Genoa, Italy

来源：

LEUKEMIA & LYMPHOMA | 2007年 / 48卷 / 03期

关键词：

D O I：

10.1080/10428190601094362

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：623 / 624

页数：2

相关论文

共 9 条

[1]

Bacigalupo A, 2005, BONE MARROW TRANSPL, V35, pS42

[2]

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease [J].

Canninga-van Dijk, MR ;

van der Straaten, HM ;

Fijnheer, R ;

Sanders, CJ ;

van den Tweel, JG ;

Verdonck, LF .

BLOOD, 2004, 104 (08) :2603-2606

[3]

Rituximab for steroid-refractory chronic graft-versus-host disease [J].

Cutler, Corey ;

Miklos, David ;

Kim, Haesook T. ;

Treister, Nathaniel ;

Woo, Sook-Bin ;

Bienfang, Don ;

Klickstein, Lloyd B. ;

Levin, Jesse ;

Miller, Katherine ;

Reynolds, Carol ;

Macdonell, Rebecca ;

Pasek, Mildred ;

Lee, Stephanie J. ;

Ho, Vincent ;

Soiffer, Robert ;

Antin, Joseph H. ;

Ritz, Jerome ;

Alyea, Edwin .

BLOOD, 2006, 108 (02) :756-762

[4]

Chronic graft-versus-host disease: where do we go from here? [J].

Farag, S .

BONE MARROW TRANSPLANTATION, 2004, 33 (06) :569-577

[5]

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission [J].

Miklos, DB ;

Kim, HT ;

Miller, KH ;

Guo, LX ;

Zorn, E ;

Lee, SJ ;

Hochberg, EP ;

Wu, CJ ;

Alyea, EP ;

Cutler, C ;

Ho, V ;

Soiffer, RJ ;

Antin, JH ;

Ritz, J .

BLOOD, 2005, 105 (07) :2973-2978

[6]

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors [J].

Miklos, DB ;

Kim, HT ;

Zorn, E ;

Hochberg, EP ;

Guo, LX ;

Mattes-Ritz, A ;

Viatte, S ;

Soiffer, RJ ;

Antin, JH ;

Ritz, J .

BLOOD, 2004, 103 (01) :353-359

[7]

Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease [J].

Okamoto, M ;

Okano, A ;

Akamatsu, S ;

Ashihara, E ;

Inaba, T ;

Takenaka, H ;

Katoh, N ;

Kishimoto, S ;

Shimazaki, C .

LEUKEMIA, 2006, 20 (01) :172-173

[8]

Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease [J].

Ratanatharathorn, V ;

Carson, E ;

Reynolds, C ;

Ayash, LJ ;

Levine, J ;

Yanik, G ;

Silver, SM ;

Ferrara, JLM ;

Uberti, JP .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) :275-279

[9]

Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody [J].

Ratanatharathorn, V ;

Ayash, L ;

Reynolds, C ;

Silver, S ;

Reddy, P ;

Becker, M ;

Ferrara, YLM ;

Uberti, JP .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (08) :505-511